Efficacy and Safety of Fecal Microbiota Transplantation and Prospect of Microbe-based Therapies for Inflammatory Bowel Disease

• Main Authors: Hoon Gil Jo, Geom Seog Seo
• Format: Article
• Language: English
• Published: Jin Publishing & Printing Co. 2021-07-01
• Series: The Korean Journal of Gastroenterology
• Subjects: fecal microbiota transplantation; inflammatory bowel diseases; microbe-based therapies
• Online Access: https://www.kjg.or.kr/journal/view.html?uid=5726&vmd=Full

The use of 5-ASA, immunomodulators, biologics, and small molecule drugs are the main treatment for inflammatory bowel disease (IBD), however, fecal microbiota transplantation (FMT) is also drawing attention as a treatment to improve intestinal dysbiosis by transplantaing normal human stool into patients with IBD. FMT demonstrates relatively good effects in inducing clinical remission in IBD, but unlike Clostridium difficile infection, multiple FMT can enhance the clinical effect. There are no reports of the long-term effectiveness and safety of FMT conducted in IBD yet, therefore, well-designed, prospective studies will be needed. Gut microbiota can affect inflammatory response, intestinal barrier function, and host metabolism, so microbe-based therapies are likely to be a new treatment option for IBD. The deeper the understanding of microbe products or effectors, the more likely it is to provide personalized therapy in IBD.